The mycobacterial ImuA'-ImuB-DnaE2 mutasome: composition and recruitment in live cells

  1. Sophia Gessner
  2. Zela Alexandria-Mae Martin
  3. Michael Anton Reiche
  4. Joana A Santos
  5. Ryan Dinkele
  6. Atondaho Ramudzuli
  7. Neeraj Dhar
  8. Timothy J de Wet
  9. Saber Anoosheh
  10. Dirk M Lang
  11. Jesse Arron
  12. Teng Leong Chew
  13. Jennifer Herrmann
  14. Rolf Müller
  15. John D McKinney
  16. Roger Woodgate
  17. Valerie Mizrahi
  18. Česlovas Venclovas
  19. Meindert Hugo Lamers
  20. Digby F Warner  Is a corresponding author
  1. University of Cape Town, South Africa
  2. Howard Hughes Medical Institute, United States
  3. Leiden University Medical Center, Netherlands
  4. University of Saskatchewan, Canada
  5. Umeå University, Sweden
  6. Helmholtz Institute for Pharmaceutical Research Saarland, Germany
  7. Swiss Federal Institute of Technology in Lausanne, Switzerland
  8. Eunice Kennedy Shriver National Institute of Child Health and Human Development, United States
  9. Vilnius University, Lithuania

Abstract

A DNA damage-inducible mutagenic gene cassette has been implicated in the emergence of drug resistance in Mycobacterium tuberculosis during anti-tuberculosis (TB) chemotherapy. However, the molecular composition and operation of the encoded 'mycobacterial mutasome' - minimally comprising DnaE2 polymerase and ImuA′ and ImuB accessory proteins - remain elusive. Following exposure of mycobacteria to DNA damaging agents, we observe that DnaE2 and ImuB co-localize with the DNA polymerase III β subunit (β clamp) in distinct intracellular foci. Notably, genetic inactivation of the mutasome in an imuBAAAAGG mutant containing a disrupted β clamp-binding motif abolishes ImuB-β clamp focus formation, a phenotype recapitulated pharmacologically by treating bacilli with griselimycin and in biochemical assays in which this β clamp-binding antibiotic collapses pre-formed ImuB-β clamp complexes. These observations establish the essentiality of the ImuB-β clamp interaction for mutagenic DNA repair in mycobacteria, identifying the mutasome as target for adjunctive therapeutics designed to protect anti-TB drugs against emerging resistance.

Data availability

Source data for all figures contained in the manuscript and SI have been deposited in Dryad; see https://datadryad.org/stash/share/fjhwiXFEIIM5-6liMtXIQn0Ehq4NIKZ3690FiR8lWyI.

The following data sets were generated

Article and author information

Author details

  1. Sophia Gessner

    Department of Pathology, University of Cape Town, Cape Town, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  2. Zela Alexandria-Mae Martin

    Department of Pathology, University of Cape Town, Cape Town, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  3. Michael Anton Reiche

    Advanced Imaging Center, Howard Hughes Medical Institute, Ashburn, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Joana A Santos

    Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  5. Ryan Dinkele

    Department of Pathology, University of Cape Town, Cape Town, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  6. Atondaho Ramudzuli

    Department of Pathology, University of Cape Town, Cape Town, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  7. Neeraj Dhar

    Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5887-8137
  8. Timothy J de Wet

    Department of Pathology, University of Cape Town, Cape Town, South Africa
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3978-5322
  9. Saber Anoosheh

    Department of Chemistry, Umeå University, Umeå, Sweden
    Competing interests
    The authors declare that no competing interests exist.
  10. Dirk M Lang

    Department of Human Biology, University of Cape Town, Cape Town, South Africa
    Competing interests
    The authors declare that no competing interests exist.
  11. Jesse Arron

    Advanced Imaging Center, Howard Hughes Medical Institute, Ashburn, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Teng Leong Chew

    Advanced Imaging Center, Howard Hughes Medical Institute, Ashburn, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Jennifer Herrmann

    Helmholtz Centre for Infection Research, Helmholtz Institute for Pharmaceutical Research Saarland, Saarbrücken, Germany
    Competing interests
    The authors declare that no competing interests exist.
  14. Rolf Müller

    Helmholtz Centre for Infection Research, Helmholtz Institute for Pharmaceutical Research Saarland, Saarbrucken, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1042-5665
  15. John D McKinney

    School of Life Sciences, Swiss Federal Institute of Technology in Lausanne, Lausanne, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0557-3479
  16. Roger Woodgate

    Laboratory of Genomic Integrity, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5581-4616
  17. Valerie Mizrahi

    Department of Pathology, University of Cape Town, Cape Town, South Africa
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4824-9115
  18. Česlovas Venclovas

    Institute of Biotechnology, Vilnius University, Vilnius, Lithuania
    Competing interests
    The authors declare that no competing interests exist.
  19. Meindert Hugo Lamers

    Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4205-1338
  20. Digby F Warner

    Department of Pathology, University of Cape Town, Cape Town, South Africa
    For correspondence
    digby.warner@uct.ac.za
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4146-0930

Funding

Eunice Kennedy Shriver National Institute of Child Health and Human Development (U01HD085531)

  • Roger Woodgate
  • Digby F Warner

Norges Forskningsråd (261669)

  • Digby F Warner

South African Medical Research Council (SHIP and Extramural Unit)

  • Valerie Mizrahi
  • Digby F Warner

National Research Foundation

  • Valerie Mizrahi
  • Digby F Warner

Howard Hughes Medical Institute (Senior International Research Scholars)

  • Valerie Mizrahi

Leids Universitair Medisch Centrum (LUMC Fellowship)

  • Meindert Hugo Lamers

National Research Foundation (104683)

  • Michael Anton Reiche

David and Elaine Potter Foundation (PhD Fellowship)

  • Zela Alexandria-Mae Martin

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,046
    views
  • 168
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sophia Gessner
  2. Zela Alexandria-Mae Martin
  3. Michael Anton Reiche
  4. Joana A Santos
  5. Ryan Dinkele
  6. Atondaho Ramudzuli
  7. Neeraj Dhar
  8. Timothy J de Wet
  9. Saber Anoosheh
  10. Dirk M Lang
  11. Jesse Arron
  12. Teng Leong Chew
  13. Jennifer Herrmann
  14. Rolf Müller
  15. John D McKinney
  16. Roger Woodgate
  17. Valerie Mizrahi
  18. Česlovas Venclovas
  19. Meindert Hugo Lamers
  20. Digby F Warner
(2023)
The mycobacterial ImuA'-ImuB-DnaE2 mutasome: composition and recruitment in live cells
eLife 12:e75628.
https://doi.org/10.7554/eLife.75628

Share this article

https://doi.org/10.7554/eLife.75628

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Angel D'Oliviera, Xuhang Dai ... Jeffrey S Mugridge
    Research Article

    The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Qian Wang, Jinxin Liu ... Qian Liu
    Research Article

    Paramyxovirus membrane fusion requires an attachment protein for receptor binding and a fusion protein for membrane fusion triggering. Nipah virus (NiV) attachment protein (G) binds to ephrinB2 or -B3 receptors, and fusion protein (F) mediates membrane fusion. NiV-F is a class I fusion protein and is activated by endosomal cleavage. The crystal structure of a soluble GCN4-decorated NiV-F shows a hexamer-of-trimer assembly. Here, we used single-molecule localization microscopy to quantify the NiV-F distribution and organization on cell and virus-like particle membranes at a nanometer precision. We found that NiV-F on biological membranes forms distinctive clusters that are independent of endosomal cleavage or expression levels. The sequestration of NiV-F into dense clusters favors membrane fusion triggering. The nano-distribution and organization of NiV-F are susceptible to mutations at the hexamer-of-trimer interface, and the putative oligomerization motif on the transmembrane domain. We also show that NiV-F nanoclusters are maintained by NiV-F–AP-2 interactions and the clathrin coat assembly. We propose that the organization of NiV-F into nanoclusters facilitates membrane fusion triggering by a mixed population of NiV-F molecules with varied degrees of cleavage and opportunities for interacting with the NiV-G/receptor complex. These observations provide insights into the in situ organization and activation mechanisms of the NiV fusion machinery.